{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:18Z","timestamp":1792719858798,"version":"4.5.0"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Thromboangiitis obliterans (TAO) is a chronic, non-atherosclerotic, progressive\ninflammatory vascular disease affecting the small- and medium-size arteries and veins of\nthe extremities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To evaluate whether long-term anticoagulation with low-molecular-weight heparin (LMWH) and warfarin is\nbeneficial for treating the inflammation and symptoms associated with TAO.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Patients with TAO who underwent anticoagulation as the mainstay of treatment were included\nin this prospective study. Rest pain relief and healing of trophic lesions (as the primary and\nsecondary endpoint) were investigated at Day 14 and after 6 months of follow-up. High sensitivity\nC-reactive protein (hsCRP), monocyte count, and ankle-brachial index (ABI) were recorded, and\nthe difference was compared before and after 2-week anticoagulation. The Chi-square test was\nused to compare the difference between anticoagulant and aspirin groups (based on the literature).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> From 2014 to 2019, 18 patients were included. Only 1 patient with wet gangrene received\nendo-therapy for a failing stent at the start of treatment. After ~14 days, 12 of 13 (92%) patients\nshowed complete ulcer healing, and 17 of 18 (94%) patients showed complete relief from rest pain.\nMonocyte-counts and hsCRP levels decreased significantly (p&lt;0.001) after a 2-week period of anticoagulation\nwith LMWH. The mean follow-up was 2.6 years (range 0.5-5 years). At 6 months, all\npatients showed relief of rest pain and complete healing of trophic lesions. All endpoints were significantly\nimproved compared with the aspirin group (p&lt;0.01), and no rest pain or ulcer\/gangrene recurred\nduring follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Anticoagulant therapy may alleviate the inflammation and symptoms of TAO.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161119666210118125424","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T07:58:42Z","timestamp":1611043122000},"page":"655-662","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-9072","authenticated-orcid":true,"given":"Jiangping","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, Shijingshan Hospital, Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuhuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Shijingshan Hospital, Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Shijingshan Hospital, Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJM200009213431207","volume":"343","author":"Olin J.W.","year":"2000","unstructured":"Olin J.W.; Thromboangiitis obliterans (Buerger\u2019s disease). N Engl J Med 2000,343(12),864-869","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1078-5884(96)80081-5","volume":"11","author":"Papa M.Z.","year":"1996","unstructured":"Papa M.Z.; Rabi I.; Adar R.; A point scoring system for the clinical diagnosis of Buerger\u2019s disease. Eur J Vasc Endovasc Surg 1996,11(3),335-339","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.bor.0000198000.58073.aa","volume":"18","author":"Olin J.W.","year":"2006","unstructured":"Olin J.W.; Shih A.; Thromboangiitis obliterans (Buerger\u2019s disease). Curr Opin Rheumatol 2006,18(1),18-24","journal-title":"Curr Opin Rheumatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00595-014-0904-6","volume":"45","author":"Sugimoto M.","year":"2015","unstructured":"Sugimoto M.; Miyachi H.; Morimae H.; Kodama A.; Narita H.; Banno H.; Yamamoto K.; Komori K.; Fate of ischemic limbs in patients with Buerger\u2019s disease based on our 30-year experience: does smoking have a definitive impact on the late loss of limbs? Surg Today 2015,45(4),466-470","journal-title":"Surg Today"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.jvs.2017.09.020","volume":"67","author":"Kim D.H.","year":"2018","unstructured":"Kim D.H.; Ko Y.G.; Ahn C.M.; Shin D.H.; Kim J.S.; Kim B.K.; Choi D.; Hong M.K.; Jang Y.; Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J Vasc Surg 2018,67(6),1769-1777","journal-title":"J Vasc Surg"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jvs.2017.03.425","volume":"66","author":"Ye K.","year":"2017","unstructured":"Ye K.; Shi H.; Qin J.; Yin M.; Liu X.; Li W.; Jiang M.; Lu X.; Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion. J Vasc Surg 2017,66(4),1133-1142.e1","journal-title":"J Vasc Surg"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","volume":"131","author":"Esmon C.T.","year":"2005","unstructured":"Esmon C.T.; The interactions between inflammation and coagulation. Br J Haematol 2005,131(4),417-430","journal-title":"Br J Haematol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","volume":"14","author":"Borensztajn K.","year":"2008","unstructured":"Borensztajn K.; Peppelenbosch M.P.; Spek C.A.; Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008,14(10),429-440","journal-title":"Trends Mol Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/QCO.0b013e328344c078","volume":"24","author":"van der Poll T.","year":"2011","unstructured":"van der Poll T.; de Boer J.D.; Levi M.; The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011,24(3),273-278","journal-title":"Curr Opin Infect Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/S0167-5273(98)00174-0","volume":"66","author":"Tanaka K.","year":"1998","unstructured":"Tanaka K.; Pathology and pathogenesis of Buerger\u2019s disease. Int J Cardiol 1998,66(Suppl. 1),S237-S242","journal-title":"Int J Cardiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.110.942383","volume":"121","author":"Piazza G.","year":"2010","unstructured":"Piazza G.; Creager M.A.; Thromboangiitis obliterans. Circulation 2010,121(16),1858-1861","journal-title":"Circulation"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/14712598.7.6.855","volume":"7","author":"Feistritzer C.","year":"2007","unstructured":"Feistritzer C.; Wiedermann C.J.; Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007,7(6),855-870","journal-title":"Expert Opin Biol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","volume":"26","author":"Rutherford R.B.","year":"1997","unstructured":"Rutherford R.B.; Baker J.D.; Ernst C.; Johnston K.W.; Porter J.M.; Ahn S.; Jones D.N.; Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997,26(3),517-538","journal-title":"J Vasc Surg"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"Norgren L.","year":"2007","unstructured":"Norgren L.; Hiatt W.R.; Dormandy J.A.; Nehler M.R.; Harris K.A.; Fowkes F.G.R.; Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg TASC II Working Group2007,45(Suppl. S),S5-S67","journal-title":"J Vasc Surg"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1016\/S0167-5273(98)00175-2","volume":"66","author":"Shionoya S.","year":"1998","unstructured":"Shionoya S.; Diagnostic criteria of Buerger\u2019s disease. Int J Cardiol 1998,66(Suppl. 1),S243-S245","journal-title":"Int J Cardiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2009.01.042","volume":"206","author":"Ma\u0142ecki R.","year":"2009","unstructured":"Ma\u0142ecki R.; Zdrojowy K.; Adamiec R.; Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis 2009,206(2),328-334","journal-title":"Atherosclerosis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.crad.2012.04.005","volume":"67","author":"Dimmick S.J.","year":"2012","unstructured":"Dimmick S.J.; Goh A.C.; Cauzza E.; Steinbach L.S.; Baumgartner I.; Stauffer E.; Voegelin E.; Anderson S.E.; Imaging appearances of Buerger\u2019s disease complications in the upper and lower limbs. Clin Radiol 2012,67(12),1207-1211","journal-title":"Clin Radiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-09-0878","volume":"74","author":"Fujii Y.","year":"2010","unstructured":"Fujii Y.; Soga J.; Nakamura S.; Hidaka T.; Hata T.; Idei N.; Fujimura N.; Nishioka K.; Chayama K.; Kihara Y.; Higashi Y.; Classification of corkscrew collaterals in thromboangiitis obliterans (Buerger\u2019s disease): relationship between corkscrew type and prevalence of ischemic ulcers. Circ J 2010,74(8),1684-1688","journal-title":"Circ J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"Kaptoge S.","year":"2010","unstructured":"Kaptoge S.; Di Angelantonio E.; Lowe G.; Pepys M.B.; Thompson S.G.; Collins R.; Danesh J.; C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet Emerging Risk Factors Collaboration2010,375(9709),132-140","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2007.02.052","volume":"49","author":"Ridker P.M.","year":"2007","unstructured":"Ridker P.M.; C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007,49(21),2129-2138","journal-title":"J Am Coll Cardiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/01.CIR.0000125690.80303.A8","volume":"109","author":"Ridker P.M.","year":"2004","unstructured":"Ridker P.M.; Cook N.; Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004,109(16),1955-1959","journal-title":"Circulation"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","volume":"17","author":"Neumann F.J.","year":"1997","unstructured":"Neumann F.J.; Ott I.; Marx N.; Luther T.; Kenngott S.; Gawaz M.; Kotzsch M.; Sch\u00f6mig A.; Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997,17(12),3399-3405","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0014-5793(92)81139-D","volume":"310","author":"Herbert J.M.","year":"1992","unstructured":"Herbert J.M.; Savi P.; Laplace M.C.; Lale A.; IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett 1992,310(1),31-33","journal-title":"FEBS Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1160\/TH06-11-0622","volume":"97","author":"Poitevin S.","year":"2007","unstructured":"Poitevin S.; Cochery-Nouvellon E.; Dupont A.; Nguyen P.; Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticles. Thromb Haemost 2007,97(4),598-607","journal-title":"Thromb Haemost"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2006.10.053","volume":"49","author":"Leroyer A.S.","year":"2007","unstructured":"Leroyer A.S.; Isobe H.; Les\u00e8che G.; Castier Y.; Wassef M.; Mallat Z.; Binder B.R.; Tedgui A.; Boulanger C.M.; Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007,49(7),772-777","journal-title":"J Am Coll Cardiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/ATVBAHA.108.180513","volume":"29","author":"Shantsila E.","year":"2009","unstructured":"Shantsila E.; Lip G.Y.; Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2009,29(10),1433-1438","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/j.thromres.2011.11.044","volume":"129","author":"Basavaraj M.G.","year":"2012","unstructured":"Basavaraj M.G.; Sovershaev M.A.; Egorina E.M.; Gruber F.X.; Bogdanov V.Y.; Fallon J.T.; \u00d8sterud B.; Mathiesen E.B.; Hansen J.B.; Circulating monocytes mirror the imbalance in TF and TFPI expression in carotid atherosclerotic plaques with lipid-rich and calcified morphology. Thromb Res 2012,129(4),e134-e141","journal-title":"Thromb Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.imbio.2012.01.008","volume":"217","author":"Gratchev A.","year":"2012","unstructured":"Gratchev A.; Sobenin I.; Orekhov A.; Kzhyshkowska J.; Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012,217(5),476-482","journal-title":"Immunobiology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/01.ATV.0000175296.02550.e4","volume":"25","author":"Nasir K.","year":"2005","unstructured":"Nasir K.; Guallar E.; Navas-Acien A.; Criqui M.H.; Lima J.A.; Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 2005,25(9),1966-1971","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=30","first-page":"95","volume":"3","author":"Gao J.P.","year":"2018","unstructured":"Gao J.P.; Huang L.H.; Wang J.L.; Perioperative changes of peripheral monocyte cells in patients with atherosclerosis obliteration. Chin J Vasc Surg 2018,3,95-100","journal-title":"Chin J Vasc Surg"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jss.2009.06.014","volume":"167","author":"Magri D.","year":"2011","unstructured":"Magri D.; Vasilas P.; Muto A.; Fitzgerald T.N.; Fancher T.T.; Feinstein A.J.; Nishibe T.; Dardik A.; Elevated monocytes in patients with critical limb ischemia diminish after bypass surgery. J Surg Res 2011,167(1),140-150","journal-title":"J Surg Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0140-6736(90)90346-7","volume":"335","author":"Fiessinger J.N.","year":"1990","unstructured":"Fiessinger J.N.; Sch\u00e4fer M.; Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990,335(8689),555-557","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1024\/0301-1526\/a000372","volume":"43","author":"Klein-Weigel P.F.","year":"2014","unstructured":"Klein-Weigel P.F.; Bimmler M.; Hempel P.; Sch\u00f6pp S.; Dreusicke S.; Valerius J.; Bohlen A.; Boehnlein J.M.; Bestler D.; Funk S.; Elitok S.; G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger\u2019s disease) and their removal by immunoadsorption. Vasa 2014,43(5),347-352","journal-title":"Vasa"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011214","volume":"7","author":"Olin J.W.","year":"2018","unstructured":"Olin J.W.; Thromboangiitis obliterans: 110 years old and little progress made. J Am Heart Assoc 2018,7(23)","journal-title":"J Am Heart Assoc"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.avsg.2016.11.012","volume":"42","author":"Tang J.","year":"2017","unstructured":"Tang J.; Gan S.; Zheng M.; Jiang Y.; Feng Y.; Miao J.; Efficacy of endovascular radiofrequency ablation for thromboangiitis obliterans (Buerger\u2019s Disease). Ann Vasc Surg 2017,42,78-83","journal-title":"Ann Vasc Surg"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1258\/vasc.2010.ra0045","volume":"19","author":"Fazeli B.","year":"2011","unstructured":"Fazeli B.; Rezaee S.A.; A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular 2011,19(3),141-153","journal-title":"Vascular"},{"key":"ref=37","volume":"2","author":"Cacione D.G.","year":"2016","unstructured":"Cacione D.G.; Baptista-Silva J.C.; Macedo C.R.; Pharmacological treatment for Buerger\u2019s disease. Cochrane Database Syst Rev 2016,2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=38","first-page":"162","volume":"25","author":"Bozkurt A.K.","year":"2006","unstructured":"Bozkurt A.K.; K\u00f6ksal C.; Demirbas M.Y.; Erdo\u011fan A.; Rahman A.; Demirkili\u00e7 U.; Ust\u00fcnsoy H.; Metin G.; Yillik L.; Onol H.; Cinar B.; Kara\u00e7elik M.; Erdin\u00e7 I.; Bolcal C.; Sayin A.G.; A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger\u2019s disease. Int Angiol Turkish Buerger\u2019s Disease Research Group2006,25(2),162-168","journal-title":"Int Angiol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1078-5884(98)80032-4","volume":"15","year":"1998","unstructured":"Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO study group. Eur J Vasc Endovasc Surg 1998,15,300-7","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jvs.2006.06.023","volume":"44","author":"Durdu S.","year":"2006","unstructured":"Durdu S.; Akar A.R.; Arat M.; Sancak T.; Eren N.T.; Ozyurda U.; Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006,44(4),732-739","journal-title":"J Vasc Surg"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1253\/circj.72.684","volume":"72","author":"Akar A.R.","year":"2008","unstructured":"Akar A.R.; Durdu S.; Baran C.; Letter by Akar et al. regarding article, \u201cEffect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger\u2019s disease\u201d. Circ J 2008,72(4),684","journal-title":"Circ J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12262-010-0186-1","volume":"73","author":"Patwa J.J.","year":"2011","unstructured":"Patwa J.J.; Krishnan A.; Buerger\u2019s Disease (Thromboangiitis obliterans)- management by Ilizarov\u2019s technique of horizontal distraction. A retrospective study of 60 cases. Indian J Surg 2011,73(1),40-47","journal-title":"Indian J Surg"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1191\/1358863x02vm452oa","volume":"7","author":"Maslowski L.","year":"2002","unstructured":"Maslowski L.; McBane R.; Alexewicz P.; Wysokinski W.E.; Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002,7(4),259-264","journal-title":"Vasc Med"},{"key":"ref=44","author":"Jorge VC","year":"2011","unstructured":"Jorge VC; Ara\u00fajo AC; Noronha C; Panarra A; Riso N; Vaz Riscado M; Buerger's disease (Thromboangiitis obliterans): a diagnostic challenge. BMJ Case Rep 2011","journal-title":"BMJ Case Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1046\/j.1538-7836.2003.t01-1-00372.x","volume":"1","author":"Maclean P.S.","year":"2003","unstructured":"Maclean P.S.; Tait R.C.; Rumley A.; McMahon A.D.; Lowe G.D.; Anticoagulation with warfarin downregulates inflammation. J Thromb Haemost 2003,1(8),1838-1839","journal-title":"J Thromb Haemost"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0741-5214(98)70060-6","volume":"28","author":"Downing L.J.","year":"1998","unstructured":"Downing L.J.; Strieter R.M.; Kadell A.M.; Wilke C.A.; Greenfield L.J.; Wakefield T.W.; Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 1998,28(5),848-854","journal-title":"J Vasc Surg"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1161\/01.ATV.0000151279.35780.2d","volume":"25","author":"Busch G.","year":"2005","unstructured":"Busch G.; Seitz I.; Steppich B.; Hess S.; Eckl R.; Sch\u00f6mig A.; Ott I.; Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005,25(2),461-466","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","volume":"140","author":"Branch K.R.","year":"2019","unstructured":"Branch K.R.; Probstfield J.L.; Eikelboom J.W.; Bosch J.; Maggioni A.P.; Cheng R.K.; Bhatt D.L.; Avezum A.; Fox K.A.A.; Connolly S.J.; Shestakovska O.; Yusuf S.; Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation 2019,140(7),529-537","journal-title":"Circulation"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"Connolly S.J.","year":"2018","unstructured":"Connolly S.J.; Eikelboom J.W.; Bosch J.; Dagenais G.; Dyal L.; Lanas F.; Metsarinne K.; O\u2019Donnell M.; Dans A.L.; Ha J.W.; Parkhomenko A.N.; Avezum A.A.; Lonn E.; Lisheng L.; Torp-Pedersen C.; Widimsky P.; Maggioni A.P.; Felix C.; Keltai K.; Hori M.; Yusoff K.; Guzik T.J.; Bhatt D.L.; Branch K.R.H.; Cook Bruns N.; Berkowitz S.D.; Anand S.S.; Varigos J.D.; Fox K.A.A.; Yusuf S.; Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet COMPASS investigators2018,391(10117),205-218","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007557.pub3","volume":"4","author":"Junqueira D.R.","year":"2017","unstructured":"Junqueira D.R.; Zorzela L.M.; Perini E.; Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2017,4(4)","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/190395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/190395\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/190395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:28:39Z","timestamp":1643779719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/190395\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161119666210118125424","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}